Nanobiotix (NBTX) Competitors

Oculis (NASDAQ:OCS) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Which has more risk and volatility, OCS or NBTX?

Oculis has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

Do institutionals & insiders believe in OCS or NBTX?

22.3% of Oculis shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor OCS or NBTX?

Oculis received 22 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 91.89% of users gave Oculis an outperform vote while only 63.16% of users gave Nanobiotix an outperform vote.

Company	Underperform	Outperform
Oculis	Outperform Votes 34 91.89%	Underperform Votes 3 8.11%
Nanobiotix	Outperform Votes 12 63.16%	Underperform Votes 7 36.84%

Which has better earnings and valuation, OCS or NBTX?

Nanobiotix has lower revenue, but higher earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$980K	847.40	-$98.92M	-$2.64	-7.20
Nanobiotix	-$11.61M	-20.91	-$42.97M	N/A	N/A

Do analysts recommend OCS or NBTX?

Oculis presently has a consensus price target of $35.33, indicating a potential upside of 85.77%. Nanobiotix has a consensus price target of $8.00, indicating a potential upside of 55.34%. Given Oculis' stronger consensus rating and higher probable upside, research analysts clearly believe Oculis is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nanobiotix	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is OCS or NBTX more profitable?

Nanobiotix has a net margin of 0.00% compared to Oculis' net margin of -8,043.28%. Nanobiotix's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,043.28%	-71.31%	-56.85%
Nanobiotix	N/A	N/A	N/A

Does the media refer more to OCS or NBTX?

In the previous week, Oculis had 4 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Oculis and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.60 beat Oculis' score of -0.11 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Oculis and Nanobiotix tied by winning 8 of the 16 factors compared between the two stocks.